Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use
暂无分享,去创建一个
[1] Poliovirus vaccine inactivated , 2018, Reactions Weekly.
[2] K. Thompson,et al. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use , 2016, BMC Infectious Diseases.
[3] K. Thompson,et al. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation , 2016, BMC Infectious Diseases.
[4] M. Pallansch,et al. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame , 2016, BMC Infectious Diseases.
[5] F. Mahoney,et al. Mass immunization with inactivated polio vaccine in conflict zones – Experience from Borno and Yobe States, North-Eastern Nigeria , 2016, Journal of public health policy.
[6] R. Price,et al. Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens , 2015, BMC Infectious Diseases.
[7] M. Pallansch,et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial. , 2015, Vaccine.
[8] N. Molodecky,et al. Needle-free jet injector intradermal delivery of fractional dose inactivated poliovirus vaccine: Association between injection quality and immunogenicity. , 2015, Vaccine.
[9] M. Pallansch,et al. An economic analysis of poliovirus risk management policy options for 2013–2052 , 2015, BMC Infectious Diseases.
[10] K. Thompson,et al. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs , 2015, BMC Infectious Diseases.
[11] M. Pallansch,et al. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs , 2015, BMC Infectious Diseases.
[12] K. Thompson,et al. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission , 2015, BMC Infectious Diseases.
[13] K. Thompson,et al. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes , 2015, BMC Infectious Diseases.
[14] M. Pallansch,et al. Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria , 2015, PloS one.
[15] M. Pallansch,et al. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. , 2015, The Journal of infectious diseases.
[16] M. Pallansch,et al. Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination , 2015, BMC Infectious Diseases.
[17] R. Sutter,et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. , 2015, Vaccine.
[18] Philip A. Eckhoff,et al. Quantifying the Impact of Expanded Age Group Campaigns for Polio Eradication , 2014, PloS one.
[19] G. Armstrong,et al. Possible Eradication of Wild Poliovirus Type 3 — Worldwide, 2012 , 2014, MMWR. Morbidity and mortality weekly report.
[20] Hiromasa Okayasu,et al. Affordable inactivated poliovirus vaccine: strategies and progress. , 2014, The Journal of infectious diseases.
[21] R. Sutter,et al. Vaccine-derived polioviruses. , 2014, The Journal of infectious diseases.
[22] K. Thompson,et al. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. , 2014, The Journal of infectious diseases.
[23] R. Sutter,et al. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. , 2014, The Journal of infectious diseases.
[24] K. Thompson,et al. Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India. , 2014, The Journal of infectious diseases.
[25] K. Thompson,et al. Modeling the dynamics of oral poliovirus vaccine cessation. , 2014, The Journal of infectious diseases.
[26] G. Kang,et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial , 2014, The Lancet.
[27] N. Grassly,et al. The role of older children and adults in wild poliovirus transmission , 2014, Proceedings of the National Academy of Sciences.
[28] M. Pallansch,et al. The potential impact of expanding target age groups for polio immunization campaigns , 2014, BMC Infectious Diseases.
[29] K. Thompson,et al. National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication , 2014, Expert review of vaccines.
[30] Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. , 2014, The Journal of infectious diseases.
[31] M. Pallansch,et al. Poliovirus vaccination options for achieving eradication and securing the endgame. , 2013, Current opinion in virology.
[32] M. Pallansch,et al. Characterizing Poliovirus Transmission and Evolution: Insights from Modeling Experiences with Wild and Vaccine‐Related Polioviruses , 2013, Risk analysis : an official publication of the Society for Risk Analysis.
[33] M. Pallansch,et al. Oral Poliovirus Vaccine Evolution and Insights Relevant to Modeling the Risks of Circulating Vaccine‐Derived Polioviruses (cVDPVs) , 2013, Risk analysis : an official publication of the Society for Risk Analysis.
[34] M. Pallansch,et al. Expert Review on Poliovirus Immunity and Transmission , 2013, Risk analysis : an official publication of the Society for Risk Analysis.
[35] M. Pallansch,et al. Review and Assessment of Poliovirus Immunity and Transmission: Synthesis of Knowledge Gaps and Identification of Research Needs , 2013, Risk analysis : an official publication of the Society for Risk Analysis.
[36] R. D. Tebbens,et al. Modeling Population Immunity to Support Efforts to End the Transmission of Live Polioviruses , 2013, Risk analysis : an official publication of the Society for Risk Analysis.
[37] M. Pallansch,et al. Preeradication Vaccine Policy Options for Poliovirus Infection and Disease Control , 2013, Risk analysis : an official publication of the Society for Risk Analysis.
[38] David Moher,et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[39] R. Sutter,et al. Priming after a fractional dose of inactivated poliovirus vaccine. , 2013, The New England journal of medicine.
[40] S. Plotkin,et al. 27 – Poliovirus vaccine—inactivated , 2013 .
[41] R. Sutter,et al. 28 – Poliovirus vaccine—live , 2013 .
[42] N. Grassly,et al. Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge , 2012, PLoS pathogens.
[43] M. Pate,et al. Outbreak of Type 2 Vaccine-Derived Poliovirus in Nigeria: Emergence and Widespread Circulation in an Underimmunized Population , 2011, The Journal of infectious diseases.
[44] M. Pallansch,et al. Economic analysis of the global polio eradication initiative. , 2010, Vaccine.
[45] N. Nathanson,et al. From Emergence to Eradication: The Epidemiology of Poliomyelitis Deconstructed , 2010, American journal of epidemiology.
[46] Kimberly M Thompson,et al. Uncertainty and Sensitivity Analyses of a Decision Analytic Model for Posteradication Polio Risk Management , 2008, Risk analysis : an official publication of the Society for Risk Analysis.
[47] Kimberly M Thompson,et al. The risks, costs, and benefits of possible future global policies for managing polioviruses. , 2008, American journal of public health.
[48] R. Sutter,et al. Poliovirus vaccine-live , 2008 .
[49] Kimberly M Thompson,et al. Risks of Paralytic Disease Due to Wild or Vaccine‐Derived Poliovirus After Eradication , 2006, Risk analysis : an official publication of the Society for Risk Analysis.
[50] Kimberly M Thompson,et al. A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. , 2005, American journal of epidemiology.
[51] M. Pallansch,et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. , 2004, JAMA.
[52] T. Edejer,et al. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector , 2003, Cost effectiveness and resource allocation : C/E.
[53] M. Pallansch,et al. Outbreak of Poliomyelitis in Hispaniola Associated with Circulating Type 1 Vaccine-Derived Poliovirus , 2002, Science.
[54] M. Pallansch,et al. Seroprevalence of antibody against poliovirus in inner-city preschool children. Implications for vaccination policy in the United States. , 1996, JAMA.
[55] Alan D. Lopez,et al. The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020. , 1996 .
[56] J. Andrus,et al. Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. , 1994, Bulletin of the World Health Organization.
[57] P. Wright,et al. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. , 1991, Reviews of infectious diseases.
[58] A. Blanc. Demographic and health surveys , 1991 .
[59] T. John,et al. Efficacy of inactivated poliovirus vaccine in India. , 1983, Bulletin of the World Health Organization.
[60] F. Maccallum. Hypogammaglobulinaemia in the United Kingdom. VII. The role of humoral antibodies in protection against and recovery from bacterial and virus infections in hypogammaglobulinaemia. , 1971, Special report series (Medical Research Council (Great Britain)).
[61] J. Paul,et al. The incubation period in human poliomyelitis and its implications. , 1947, Journal of the American Medical Association.
[62] Census Figures.—(I.) , 1910 .